Pfizer Inc
NYSE : PFE$29.58−0.04%Oct 16 close
Financials
A full-history view is not available for the cash flow statement yet. This is the statement exactly as one filing printed it.
Consolidated Statements of Cash Flows
USD · reported units. Click a value to inspect its source.
| Reported line item | Jan 1, 2023 to Dec 31, 2023 (current) | Jan 1, 2022 to Dec 31, 2022 | Jan 1, 2021 to Dec 31, 2021 |
|---|---|---|---|
| Net income before allocation to noncontrolling interests | |||
| Discontinued operationsnet of tax | |||
| Net income from continuing operations before allocation to noncontrolling interests | |||
| Depreciation and amortization | |||
| Asset write-offs and impairments | |||
| Deferred taxes | |||
| Share-based compensation expense | |||
| Benefit plan contributions in excess of expense/income | |||
| Inventory write-offs and related charges associated with COVID-19 products | |||
| Other adjustments, net | |||
| Trade accounts receivable | |||
| Inventories | |||
| Other assets | |||
| Trade accounts payable | |||
| Other liabilities | |||
| Other tax accounts, net | |||
| Net cash provided by/(used in) operating activities from continuing operations | |||
| Net cash provided by/(used in) operating activities from discontinued operations | |||
| Net cash provided by/(used in) operating activities | |||
| Purchases of property, plant and equipment | |||
| Purchases of short-term investments | |||
| Proceeds from redemptions/sales of short-term investments | |||
| Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less | |||
| Purchases of long-term investments | |||
| Proceeds from redemptions/sales of long-term investments | |||
| Acquisitions of businesses, net of cash acquired | |||
| Dividend received from the Consumer Healthcare JV | |||
| Other investing activities, net | |||
| Net cash provided by/(used in) investing activities from continuing operations | |||
| Net cash provided by/(used in) investing activities from discontinued operations | |||
| Net cash provided by/(used in) investing activities | |||
| Proceeds from short-term borrowings | |||
| Payments on short-term borrowings | |||
| Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less | |||
| Proceeds from issuances of long-term debt | |||
| Payments on long-term debt | |||
| Purchases of common stock | |||
| Cash dividends paid | |||
| Other financing activities, net | |||
| Net cash provided by/(used in) financing activities | |||
| Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents | |||
| Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents | |||
| Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period | |||
| Cash and cash equivalents and restricted cash and cash equivalents, at end of period | |||
| Income taxes | |||
| Interest paid | |||
| Interest rate hedges | |||
| Right-of-use assets obtained in exchange for lease liabilities |
48 line items · 3 reported periodsOriginal filing order · parentheses indicate negative amounts
Each column reflects this filing’s presentation. Original line items and period dates are preserved.